Vice President, Translational Research

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Vice President reporting to the SVP of Translational Research in Biology, the individual will collaborate with colleagues in Research and Development to serve as the scientific and organizational leader of the Cancer Pharmacology function and help shape the translational research strategy supporting Revolution Medicines' discovery and development portfolio. The cancer pharmacology effort is accountable for delivering mechanistic, efficacy, PK/PD, and combination strategy insights that enable candidate selection, IND-enabling studies, translational biomarker strategies, and clinical development decisions. The candidate will serve as a key scientific leader in disease area strategy discussions, helping prioritize indications, combination opportunities, biomarker hypotheses, and portfolio investments. Functional responsibilities include leadership, mentoring and development of a productive cancer pharmacology group, a facile translational research operations group, and AI/ML integration for modern data infrastructure and analytics. The leader is expected to work cross-functionally across a broad and growing R&D organization, including functions driving ADME, safety, regulatory affairs, and clinical development. We are seeking an experienced and visionary leader with strong interpersonal skills and an ability to lead a strong and diverse translational research team. The ideal candidate will: Define and implement forward translation strategies for RAS-driven diseases supervising an internal team of highly experienced and accomplished cancer pharmacologists to drive in vivo pharmacology in parallel with scientific discovery and combination strategies. Drive efforts to organize and harmonize large data sets across the organization, as part of a digital data transformation initiative, and accelerate integration and analysis of large scale preclinical and clinical datasets into our translational research strategy. Champion the integration of advanced computational approaches, AI/ML methodologies, and modern data infrastructure to enable data-driven decision making across discovery, translational research, and development. Be accountable for a sophisticated core operations group that can meet diverse needs across research, including international preclinical CRO management and internal regulatory and operational interactions. Leverage strong cross-functional skills to develop productive collaborations with diverse groups across the organization including research, development, and project teams. Engage with external collaborations including academic centers, CROs, non-profit organizations and experts to drive execution of key projects and bring in new technologies. Represent Revolution Medicines externally through scientific publications, conference presentations, advisory boards, and strategic collaborations. Be a strategic leader and thought partner for disease area strategy initiatives to accelerate our pipeline, stay up to date with industry trends to identify future translational gaps and opportunities, develop plans to implement and help programs pivot to ensure future success. Required Skills, Experience, and Education: PhD in oncology, pharmacology, cancer biol…